-
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML October 10, 2019 Chester, NJ –…October 10, 2019 -
Interview with Randy Milby, CEO
Interview with Randy Milby, CEO April 5, 2019 This is the second post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in…April 5, 2019
Loading posts...
Recent Posts
- Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
- Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
- February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
- Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
- Hillstream BioPharma Provides Business Review with Key Pipeline Updates